Clinical Trial Update: Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase IIIb trial evaluating safety and tolerability of Herceptin SC with Perjeta and docetaxel in HER2-positive advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Herceptin SC (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED